retatrutide clinical trial thailand SURMOUNT-1 Tirzepatide — 22.5% Weight Loss Triple hormone receptor agonist retatrutide

The maximum studied dose in clinical trials was 12 mg weekly

Every-other-day dosing falls between twice weekly and three times weekly, with a 30% peak reduction and a peak-to-trough ratio of 1.8

Many individuals expect immediate weight loss

They are different molecules with different mechanisms, different efficacy profiles, and different regulatory statuses

We can supply up to a 90-day supply as your prescription allows

71 These data, together with the finding of no effect of prior weight-reduction strategies on hard outcomes in HF, signify very likely beneficial effects of GLP-1RAs that are independent of weight loss